• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21597 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Cardiac surgery registry. An international review]
2009     Committee for New Health Technology Assessment (CNHTA) [Cardio detect(h-FABP)]
2018     Andalusian Health Technology Assessment Area (AETSA) [Cardiopoietic stem cells for the treatment of heart failure secondary to myocardial ischemia]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Cardiopulmonary resuscitation in COVID-19 patients]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Cardiovascular prevention at old ages, competing risks, competing costs, frailty and indirect medical costs]
2013     Andalusian Health Technology Assessment Area (AETSA) [CardioWest™ TAH-t. Total artificial heart]
2020     Andalusian Health Technology Assessment Area (AETSA) [Care model for women with endometriosis. Systematic review of clinical practice guidelines]
2017     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Care needs assessment tools]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma; combination with dexamethasone alone) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Addendum to Commission A17-38]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Addendum to Commission A21-08]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2008     Committee for New Health Technology Assessment (CNHTA) [Caries diagnosis with laser fluorescence(Diagnodent)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cariprazine (schizophrenia) - Addendum to Commission A18-25]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Carotid echo doppler for plaque area measurement in cardiovascular risk stratification]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Case and control study: efficiency of psychoeducational treatment of the overload experienced by family members of bipolar patients]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Case finding in osteoporosis, how to implement current guidelines? A randomized comparison of two implementation strategies in general practice]
2012     The Swedish Council on Health Technology Assessment (SBU) [Case finding, diagnosis and follow up of patients with affective disorders]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Casirivimab and imdevimab to treat Covid-19 in patients negative for the Omicron genotype]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) - Benefit assessment according to §35a Social Code Book V]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Catalan arthroplasty register. 2nd report (data 2005-2010)]
2010     The Swedish Council on Health Technology Assessment (SBU) [Catheter ablation for atrial fibrillation (update)]
2005     The Swedish Council on Health Technology Assessment (SBU) [Catheter ablation of atrial fibrillation - early assessment briefs (Alert)]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Catheter-directed mechanical thrombolysis in thromboembolic disease]
2008     Committee for New Health Technology Assessment (CNHTA) [CBFB/MYH11 rearrangement, Quantification [Real-time RT-PCR]]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [CD34+ cells (beta thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [CD4 lymphocyte activity (bioluminescent assay)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cefiderocol (infections) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftazidime/avibactam (bacterial infection) - Assessment according to §35a (para. 1c) Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ceftazidime/avibactam in severe infections]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (acute pyelonephritis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (bacterial infections < 18 years) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (complicated intra-abdominal infections) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (complicated urinary tract infections) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (hospital-acquired pneumonia) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenegermin (moderate or severe neurotrophic keratitis) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenobamate (epilepsy) - Addendum to Commission A21-78]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenobamate (epilepsy) - Benefit assessment according to §35a Social Code Book]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Central auditory processing disorder diagnosis]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Centralized Implementation of accurate and efficient preoperative staging using multislice CT, endoultrasonographic fine needle biopsy (EUS-FNA) and positron emission tomography (FDG-PET) in esophageal cancer patients: Cimple study]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Cerebrospinal fluid neurotransmitter screening in encephalopathies]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Cerenkov lluminescence imaging system for intraoperative assessment of surgical margins in breast, prostate, and gastrointestinal cancer]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (lung cancer): Addendum to Commission A16-62]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (lung cancer): benefit assessment according to §35a Social Code Book V; expiry of the decision
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib for the treatment of ALK-positive metastatic non-small cell lung cancer]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib in lung cancer]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cerliponase alfa (neuronal ceroid lipofuscinosis type 2) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cerliponase alfa (neuronal ceroid lipofuscinosis) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Cerliponase alfa in neuronal ceroid lipofuscinosis type 2]
2017     Agenzia nazionale per i servizi sanitari regionali (Agenas) [Cervical and lumbar total disc replacement - HTA report adaptation]
2010     Haute Autorite de sante (HAS) [Cervical length measurement with transvaginal ultrasonography to predict spontaneous preterm birth]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cessation of smoking in essential hypertension - Rapid report]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Cetuximah given in combination for patients with colorectal cancer]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Checklist for ethical and legal domains analysis]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Chemoembolization and radioembolization for the treatment of liver metastases]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Chlamydia screening with home testing - a health technology assessment]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cholic acid - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cholinesterase inhibitors in Alzheimer's disease]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [ChondroCelect® in patients with knee cartilage injury]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Chromosomal microarrays for the etiologic diagnosis in patients with intellectual disability, developmental delay or autism spectrum]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Chronic fatigue syndrome: state of the evidence and assessment of intervention modalities in Quebec]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Chronic hepatitis C. Combination therapy IFN and ribavirin]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Chronic low back pain: the appropriate use of diagnostic imaging procedures]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Chronic periodontitis - prevention, diagnosis and treatment]
2014     The Swedish Council on Health Technology Assessment (SBU) [Chronic ulcers in the elderly – prevention and treatment]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Cidofovir for the treatment of recurrent respiratory papillomatosis]
2010     The Swedish Council on Health Technology Assessment (SBU) [Cilostazol for treatment of intermittent claudication]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cipaglucosidase alfa (Pompe disease) – Addendum to Project A23-79]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cipaglucosidase alfa (Pompe disease) – Benefit assessment according to § 35a Social Code Book (SGB) V]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Circulating tumour cells in breast cancer: clinical use of the CellSearch® test]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Classification of disease severity for neuro- and trauma rehabilitation Part 3: Status quo in Austria]
2008     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Clavicular fractures - a systematic review about efficacy and safety of different treatment options]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Clinical effectiveness and cost-effectiveness of central venous catheters treated with minocycline and rifampicin in preventing bloodstream infections in intensive care patients]
2014     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Clinical effectiveness and cost-effectiveness of fissure sealants in children and adolescents with a high caries risk]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Clinical effectiveness and cost-effectiveness of non-invasive telemonitoring on patients with heart failure]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Clinical effectiveness and safety of robotic surgery]
2005     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Clinical effectiveness of carvedilol in comparison to -blockers, systematic review of the clinical and economic literature]
2005     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Clinical effectiveness of indapamide; systematic review of the clinical and economic literature]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry. Systematic Review]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry: Maple Syrup Urine Disease, Homocystinuria, Glutaric Aciduria Type I, Isovaleric Acidaemia, Long-chain 3-Hydroxyacyl CoA Dehydrogenase Deficiency]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part III: carnitine uptake deficiency (CUD); short-chain acyl-CoA dehydrogenase deficiency (SCADD); very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: Beta-kethiolase deficiency (BKT); 3-Hydroxy-3-methyl glutaric aciduria (HMG)]